As we move toward a value-driven health care system, the focus should be on outcomes that matter most to patients, such as how medicines make patients feel, whether they can return to work or how their quality of life has improved. Advancing research and methods related to value assessment is an important step toward that goal. At ISPOR 2019, a conference about health economics and outcomes research and its use in health care decisions, thought leaders discussed how to better measure value in health care.
As part of The Value Collaborative, we hosted a reception in conjunction with the Office of Health Economics titled, “Moving the Needle on Value.” The reception featured brief remarks from individuals at the leading edge of this research, including:
- Innovation and Value Initiative’s Jenn Bright, who talked about whether value assessments currently capture what matters most to patients and society
- Harvard Medical School’s Anupam Jena, who discussed the reasons for and implications of ignoring value in other areas of health care beyond medical technology
- Former ISPOR president and the Office of Health Economics’ Adrian Towse, who highlighted how we can increase information on value for the costliest aspects of the health care system
Over the course of the conference, several other groups who recently received funding from the PhRMA Foundation Value Assessment Initiative discussed how we can better assess value. These groups include:
- The Center for Enhanced Value Assessment (CEVA): Headquartered within the Center for the Evaluation of Value and Risk in Health (CEVR) at Tufts Medical Center, this organization aims to explore the incorporation of non-traditional elements of value into cost-effective analyses.
- Patient-Driven Values in Healthcare Evaluation (PAVE): A unique collaboration between the University of Maryland School of Pharmacy, the National Health Council, patient community leaders, and payer and industry leaders, this organization is dedicated to developing and advancing new methods to incorporate the patient perspective into value assessment and value-based decision-making.
- Pharmaceutical Value (pValue): Headquartered within the University of Colorado’s Anschutz Medical Campus, this initiative aims to apply and test novel multi-criteria decision-making methods for value assessment that encourage stakeholder engagement and build in non-traditional elements of value to a decision tool where cost-effectiveness analysis, by definition, has fallen short.
- Research Consortium for Health Care Value Assessment (Value Consortium): This partnership between Altarum and VBID Health aims to move the framework for value-based decision making from how much we spend to how well it is spent by identifying high- and low-value clinical services, tracking the use of such services and helping to ensure that consumer and patient preferences are incorporated into the health care decision-making process.
To learn more about how we can better assess value, visit www.phrma.org/value-collaborative.
Samantha Dougherty
Samantha Dougherty is a Deputy Vice President of Policy and Research at PhRMA. Her primary role is to develop and manage a broad portfolio of research projects related to the use and value of medicines. She has authored and been involved in numerous academic and non-academic projects that have been published in peer-reviewed journals or presented at scientific conferences. Samantha also serves as a lead subject matter expert on cost savings from use of medicines, evidence related to adherence, productivity and achievement of better outcomes. She received a B.S. in Economics from the University of Maryland College Park and a Ph.D. in Pharmaceutical Health Services Research from the University of Maryland Baltimore.
Incomplete evaluations undermine patient access to transformational medicine
You won’t fix what you don’t value: Two reasons why traditional cost-effective analyses can perpetuate health inequities
PhRMA presents research at ISPOR 2022
Innovative contracts continue to gain traction and improve quality of care
Study finds nearly half of payers believe innovative contracts can lead to lower patient out-of-pocket costs
Growth in innovative, value-based contracts holds promise for the health system and for patients
Innovative contracts drive access for patients and value for the system
ICYMI: Patients saved nearly $800,000 out of pocket through innovative contracting arrangements
Low-value health care costs $345B each year and provides little benefit
Addressing barriers that inhibit value-based contracts
Guest post: Value-based agreements can improve outcomes and even save patients money at the pharmacy counter
New data show how ICER’s value framework could prevent or delay access to treatments for Medicaid patients across the country
5 Ways to improve ICER’s value assessment framework
New analysis shows 820,000 prescriptions would be in jeopardy if ICER’s value framework is used in Medicaid
Value assessments should include all the outcomes that matter to patients and families
Event tomorrow: Leaders convene to discuss solutions to advance value-driven health care
New whitepaper identifies reasons why ICER’s cost-effectiveness analyses are not useful for payers
Guest post: Developing new payment models to ensure patients have access to high-investment therapies
Number of value-based contracts continues to rise
ICER’s budget impact threshold: Sounding a false alarm on affordability and access
PhRMA submission to HHS on blueprint to lower drug prices and reduce out-of-pocket costs
How ICER’s assessment of a new class of migraine treatments fails patients
Aspen Spotlight Health: Discussing the forefront of innovation
New analysis shows that HTA organizations may frequently restrict access to cancer treatments
New analysis shows negative impact of ICER’s value framework on patient access in Medicare Part B
ICYMI: Recent survey adds to growing body of research on barriers to innovative payment approaches
Event tomorrow: Improving patient access to lifesaving medicines
Reality check: Value-based contracts are good for patients
Video: Barriers to results-based contracts
Improving care quality by engaging patients in shared decision making
ICYMI: Research shows promise of innovative payment arrangements in reducing costs, improving access
Clarity around anti-kickback statute needed to promote innovative payment arrangements
Video: What is a results-based contract?
PhRMA Foundation recognizes inaugural Challenge Award recipients
Johnson & Johnson, Pfizer, Walgreens and other CEOs discuss value in the future of health care
The journey to better health care requires a holistic view
Medicare Monday: How Part B has evolved over the years
Modernizing FDA regulations to advance a value-driven health care system
PhRMA CEO in Forbes - How to negotiate better deals for prescription medicines
ICYMI: Avalere and FasterCures develop new value framework from patient perspective
ICYMI: Innovative payment models helping provide patient access to new medicines
RA medicines often demonstrate far greater benefits to patients than initially understood
New analysis: More than half of patients’ out-of-pocket spending for brand medicines is based on full list price
Stakeholders Agree: Modernize the legal framework to support move to value-driven health care
How do multiple sclerosis patients define value?
PhRMA CEO talks White House meeting, innovation & jobs with POLITICO’s Pulse Check
VIDEO: PhRMA CEO discusses #GOBOLDLY campaign and White House meeting with CNNMoney’s Maggie Lake
The Value Collaborative: Advancing private market solutions to achieve better health, lower costs
Assessing value top of mind at ISPOR 2019
The Value Collaborative
Value-Driven Health Care
Assessing value top of mind at ISPOR 2019
Assessing value top of mind at ISPOR 2019